- Location
-
Deutsche Nationalbibliothek Frankfurt am Main
- Extent
-
Online-Ressource
- Language
-
Englisch
- Bibliographic citation
-
Role of Crizotinib in previously treated non-small-cell lung cancer ; volume:03 ; number:02 ; year:2014 ; pages:138-140
South Asian journal of cancer ; 03, Heft 02 (2014), 138-140
- Contributor
-
Gupta, Sunil Kumar
- DOI
-
10.4103/2278-330X.130468
- URN
-
urn:nbn:de:101:1-2021022619312245515608
- Rights
-
Open Access; Der Zugriff auf das Objekt ist unbeschränkt möglich.
- Last update
-
15.08.2025, 7:25 AM CEST
Data provider
This object is provided by:
Deutsche Nationalbibliothek. If you have any questions about the object, please contact the data provider.
Deutsche Nationalbibliothek. If you have any questions about the object, please contact the data provider.
Associated
- Gupta, Sunil Kumar
Other Objects (12)
Non-small-cell lung cancer
Cost Effectiveness of Nivolumab in Patients with Advanced, Previously Treated Squamous and Non-squamous Non-small-cell Lung Cancer in England
Pharmacometric applications in non-small-cell lung cancer
Long-term outcomes in radically treated synchronous vs. metachronous oligometastatic non-small-cell lung cancer
Gefitinib (Iressa, ZD 1839) A Potential Chemotherapy Sensitizer in Previously Chemotherapy Nonresponded Advanced Non-Small-Cell Lung Cancer Patients
Brain Penetration of Lorlatinib: Cumulative Incidences of CNS and Non-CNS Progression with Lorlatinib in Patients with Previously Treated ALK-Positive Non-Small-Cell Lung Cancer
Two-year survival with nivolumab in previously treated advanced non–small-cell lung cancer: a real-world pooled analysis of patients from France, Germany, and Canada
FDG-PET radiomics for response monitoring in non-small-cell lung cancer treated with radiation therapy
Perioperative immunotherapy for resectable non-small-cell lung cancer
Clusterin modulates transdifferentiation of non-small-cell lung cancer
Small nucleolar RNA signatures as biomarkers for non-small-cell lung cancer
First-Line Immunotherapy in Advanced Non-Small-Cell Lung Cancer
Non-small-cell lung cancer
Cost Effectiveness of Nivolumab in Patients with Advanced, Previously Treated Squamous and Non-squamous Non-small-cell Lung Cancer in England
Pharmacometric applications in non-small-cell lung cancer
Long-term outcomes in radically treated synchronous vs. metachronous oligometastatic non-small-cell lung cancer
Gefitinib (Iressa, ZD 1839) A Potential Chemotherapy Sensitizer in Previously Chemotherapy Nonresponded Advanced Non-Small-Cell Lung Cancer Patients
Brain Penetration of Lorlatinib: Cumulative Incidences of CNS and Non-CNS Progression with Lorlatinib in Patients with Previously Treated ALK-Positive Non-Small-Cell Lung Cancer
Two-year survival with nivolumab in previously treated advanced non–small-cell lung cancer: a real-world pooled analysis of patients from France, Germany, and Canada
FDG-PET radiomics for response monitoring in non-small-cell lung cancer treated with radiation therapy
Perioperative immunotherapy for resectable non-small-cell lung cancer
Clusterin modulates transdifferentiation of non-small-cell lung cancer
Small nucleolar RNA signatures as biomarkers for non-small-cell lung cancer
First-Line Immunotherapy in Advanced Non-Small-Cell Lung Cancer
Non-small-cell lung cancer
Cost Effectiveness of Nivolumab in Patients with Advanced, Previously Treated Squamous and Non-squamous Non-small-cell Lung Cancer in England
Pharmacometric applications in non-small-cell lung cancer
Long-term outcomes in radically treated synchronous vs. metachronous oligometastatic non-small-cell lung cancer
Gefitinib (Iressa, ZD 1839) A Potential Chemotherapy Sensitizer in Previously Chemotherapy Nonresponded Advanced Non-Small-Cell Lung Cancer Patients
Brain Penetration of Lorlatinib: Cumulative Incidences of CNS and Non-CNS Progression with Lorlatinib in Patients with Previously Treated ALK-Positive Non-Small-Cell Lung Cancer
Two-year survival with nivolumab in previously treated advanced non–small-cell lung cancer: a real-world pooled analysis of patients from France, Germany, and Canada
FDG-PET radiomics for response monitoring in non-small-cell lung cancer treated with radiation therapy
Perioperative immunotherapy for resectable non-small-cell lung cancer
Clusterin modulates transdifferentiation of non-small-cell lung cancer
Small nucleolar RNA signatures as biomarkers for non-small-cell lung cancer